

1 **Genomic characterization of Dengue virus circulation in Ethiopia.**

2
3 Adugna Abera^{1,2†*}, Houriiyah Tegally^{3†*}, Geremew Tasew¹, Eduan Wilkinson³, Abraham Ali¹,
4 Feyisa Regasa¹, Molalegne Bitew⁵, Lucious Chabuka³, Gaspary Mwanyika³, Derek Tshiabuila³,
5 Jennifer Giandhari⁴, Sureshnee Pillay⁴, Jenicca Poogavanan³, Monika Moir³, CLIMADE
6 Consortium[#], Moritz U.G. Kraemer^{7,8}, Kamran Khan^{9,10}, Carmen Huber⁹, Getachew Tollera¹,
7 Tobias F. Rinke de Wit⁶, Cheryl Baxter³, Richard Lessells⁴, Dawit Wolday^{1,11}, Dereje Beyene^{2§},
8 Tulio de Oliveira^{3,4§}

9
10 Authors affiliations:

11 ¹Ethiopian Public Health Institute, Addis Ababa, Ethiopia

12 ²Department of Microbial, Cellular, and Molecular Biology, College of Natural and Computational
13 Sciences, Addis Ababa University, Addis Ababa, Ethiopia

14 ³Centre for Epidemic Response and Innovation (CERI), School of Data Science and
15 Computational Thinking, Stellenbosch University, South Africa

16 ⁴KwaZulu-Natal Research Innovation and Sequencing Platform (KRISP), Nelson R Mandela
17 School of Medicine, University of KwaZulu-Natal, Durban, South Africa

18 ⁵Bio and Emerging Technology Institute, Addis Ababa, Ethiopia

19 ⁶Amsterdam Institute for Global Health and Development (AIGHD), Department of Global
20 Health, Amsterdam University Medical Centre, University of Amsterdam, Amsterdam, the
21 Netherlands

22 ⁷Department of Biology, University of Oxford, Oxford, UK

23 ⁸Pandemic Sciences Institute, University of Oxford, Oxford, UK

24 ⁹BlueDot, Toronto, ON, Canada

25 ¹⁰Department of Medicine, Division of Infectious Diseases, University of Toronto, Toronto, ON,
26 Canada

27 ¹¹Department of Biochemistry and Biomedical Sciences, Michael G. DeGroot Institute for
28 Infectious Diseases Research (IIDR), and McMaster Immunology Research Center (MIRC),
29 Health Sciences, McMaster University, Hamilton, Ontario, Canada

30 †These authors contributed equally to this work.

31 § Co-senior authors

32 # CLIMADE consortium author list and affiliations in supplementary material

33

34 **Corresponding Author Contact Information**

35 * Authors to whom correspondence should be addressed.

36 Adugna Abera, Department of Microbial, Cellular, and Molecular Biology, College of Natural and
37 Computational Sciences, Addis Ababa University, Addis Ababa, Ethiopia and Ethiopian Public
38 Health Institute, Arbanoch Street, Addis Ababa, Ethiopia; email: adugnabe@yahoo.com.

39 Houriiyah Tegally, Centre for Epidemic Response and Innovation (CERI), School of Data Science
40 and Computational Thinking, Stellenbosch University, South Africa; email: houriiyah@sun.ac.za.

41

42 **ABSTRACT**

43 In Ethiopia, dengue virus (DENV) infections have been reported in several regions, however, little
44 is known about the circulating genetic diversity. Here, we conducted clinical surveillance for
45 DENV during the 2023 nationwide outbreak and sequenced DENV whole genomes for the first
46 time in Ethiopia. We enrolled patients at three sentinel hospital sites. Using RT-PCR, we screened
47 serum samples for three arboviruses followed by serotyping and sequencing for DENV-positive
48 samples (10.4% of samples). We detected two DENV serotypes (DENV1 and DENV3).
49 Phylogenetic analysis identified one transmission cluster of DENV1 (genotype III major lineage
50 A), and two clusters of DENV3 (genotype III major lineage B). The first showed close
51 evolutionary relationship to the 2023 Italian outbreak and the second cluster to Indian isolates. Co-
52 circulation of DENV1 and DENV3 in some regions of Ethiopia highlights the potential for severe
53 dengue. Intensified surveillance and coordinated public health response are needed to address the
54 threat of severe dengue outbreaks.

55 **Key words:** Serotypes, Genotypes, Phylogenetic analysis, Seasonality, Human mobility, Dengue,
56 Ethiopia.

57

58 **Introduction**

59 Dengue virus (DENV) is primarily transmitted by *Aedes* mosquitoes and causes significant
60 epidemics in tropical and subtropical regions. Since the beginning of 2023, over 5 million cases
61 and 5,000 dengue-related deaths have been reported in over 80 countries (1). In 2023, the WHO
62 African region reported 171,991 suspected cases, 70,223 of which were confirmed cases with 753
63 fatalities. Outbreaks have been reported in 15 African countries: Burkina Faso has accounted for
64 85% of cases, followed by Ethiopia (8.2%), Mali (2.5%), and Côte d'Ivoire (2.2%) (2).

65 Ethiopia has been facing several outbreaks of dengue fever since 2013. The first recorded outbreak
66 was reported in Dire Dawa City, which affected 9,441 individuals (3). A second outbreak occurred
67 in Somale Godey Town and the Afar Region in 2014 and 2015, respectively (4). Since 2015, there
68 has been an increase in the number of severe febrile illness cases in Godey, Dire Dawa town, and
69 the Afar area, with no apparent cause. The first outbreak started in April 2023 in the Afar region,
70 followed by Dire Dawa and the neighboring regions of Amhara and Oromia. There have been
71 27,577 reported cases and 21 deaths in 12 districts in the eastern part of Ethiopia (1,5).

72 DENV is a single-stranded positive-sense RNA virus, and its genome encodes three structural and
73 seven nonstructural proteins. There are four serotypes of DENV, namely DENV1, DENV2,
74 DENV3, and DENV4 (8, 9). When an individual is infected with one serotype, they develop
75 immunity to that specific serotype for a long time. However, they only develop partial immunity
76 to the other serotypes. In case of subsequent infections with a different serotype, the risk of severe
77 dengue increases. Each serotype of the virus is further divided into several genotypes, which are
78 categorized based on the envelope gene (E gene). However, different genotypes of the same
79 serotype may vary in their ability to infect host cells and cause severe forms of the disease. Based
80 on the genetic characterization, five genotypes have been defined for DENV1, six for DENV2,
81 five for DENV3, and four for DENV4 (10-13). Recently, a nomenclature system has been
82 proposed to further subdivide genotypes into major and minor lineages to aid global monitoring
83 efforts (14).

84 Studies have shown that during dengue outbreaks, the emergence of new serotypes or changes in
85 circulating genotypes of the virus in a particular region can lead to more severe outbreaks (15,16).
86 Given that there are currently no approved medical countermeasures for treating severe dengue,
87 and vaccines are currently not available to most countries, it is crucial to continuously monitor the

88 circulating dengue genetic diversity in endemic areas. This information will be instrumental in
89 developing and evaluating vaccines and treatments (17), and in responding effectively to dengue
90 outbreaks.

91 Although there have been multiple outbreaks and geographical expansion of DENV in Ethiopia,
92 there is currently no documented characterization of the circulating diversity of DENV, and no
93 publicly available whole genome sequences. In this study, we address this gap by identifying
94 circulating DENV serotypes and genotypes among individuals with febrile illness in three hospital-
95 based sentinel sites in Ethiopia and conduct phylogenetic analysis to determine spatial and
96 temporal patterns of dengue transmission in Ethiopia.

97 **Materials and methods**

98 *Patient characteristics and study settings*

99 We conducted a cross-sectional hospital-based study in Afar, Gambela, and Dire Dawa city
100 administration (Supplementary Figure 1). Between December 2022 and November 2023, we
101 enrolled outpatients and inpatients presenting with fever ($>37.5^{\circ}\text{C}$) at three major public hospitals
102 in Dubti (Afar region), Dilchora (Dire Dawa), and Gambela. These hospitals serve as sentinel sites
103 for acute febrile illnesses in the country and were selected due to their previous history of arbovirus
104 outbreaks and serological evidence for arboviruses (5, 18).

105 *Recruitment of participants*

106 We obtained informed consent from all participants aged 18 years and older. For individuals aged
107 1 to 17 years, we obtained informed consent from a parent or guardian and, where appropriate,
108 assent from the child.

109 *Eligibility/exclusion criteria*

110 The inclusion criteria for the study were: a fever of more than 37.5°C , following the 2009 WHO
111 Dengue classification (19), joint pain, rash, headache, myalgia, retro-ocular discomfort, stomach
112 pain, and hemorrhagic presentation.

113 Patients with severe, and established chronic clinical illnesses such as people living with HIV,
114 malignancies, and known metabolic disorders were excluded from the study.

115

116 *Sample collection and processing*

117 Each participant provided five milliliters of whole blood, which was collected into serum separator
118 tubes. At the Afar site, blood sample collection took place between April 25, 2023, and May 15,
119 2023. The serum was isolated and collected in tubes containing 1 ml DNA/RNA shield and stored
120 at -20 °C during field collections. It was then transported in a cold chain to the laboratory of the
121 Ethiopian Public Health Institute (EPHI) and stored at -20 °C until analysis for PCR and
122 sequencing. Blood samples from Dire Dawa and Gambela sites were collected between June 2023
123 and October 2023, stored at -20 °C, and then shipped in a cold chain to the laboratory of the EPHI,
124 where they were stored at -80 °C until analysis.

125 *RNA extraction and PCR amplification*

126 We performed RNA extraction within five days of receiving the serum samples at the EPHI
127 laboratory from each site. The RNA extraction was carried out using a Bioer NPA-32P instrument
128 (Bior Technology, Zhejiang, China), which is a high-throughput automated workstation. We used
129 the MagaBio Plus RNA Purification (Bior Technology, Zhejiang, China) for the extraction
130 process, following the manufacturer's instructions. Briefly, we prepared 96-well plates and added
131 300 µl of thawed and briefly vortexed serum samples to columns #1 and #7. The plate was then
132 placed into the instrument, which agitated the plates every 10 seconds for 9 minutes until the
133 extraction was completed, resulting in 70 µl RNA extracts.

134 The remaining serum samples from the Afar region were stored at -20°C for later whole genome
135 sequencing. Meanwhile, samples from the Dire Dawa and Gambela sites were stored at -80°C. In
136 February 2024, some of the qualifying serum samples were sent to the CERI and KRISP
137 laboratories in South Africa for whole genome sequencing.

138 On the same day that we extracted the RNA, we used the CDC Trioplex real-time RT-PCR assay
139 to screen for arboviral infections such as DENV, CHIKV, and ZIKV. This assay includes a set of
140 published oligonucleotide primers and dual-labeled hydrolysis Taqman probes. To run the test, we
141 combined 10 µl of sample RNA with 12.5 µl of PCR master mix reaction buffer (SuperScript™
142 III One-Step RT-PCR System with Platinum™ Taq DNA Polymerase, ThermoFischer Scientific),
143 1 µM virus-specific primers, 0.3 µM dengue-specific probe, 0.15 µM chikungunya-specific probe,

144 0.15 μ M Zika virus-specific probe, and nuclease-free water in a 96-well optical PCR plate to make
145 a final reaction volume of 25 μ l. We then carried out reverse transcription (RT) for 30 minutes at
146 50°C, followed by RT inactivation for 2 minutes at 95°C, fluorescence detection for 15 seconds at
147 95°C, and annealing for 1 minute at 60°C. Additionally, the assay includes an internal control
148 reaction targeting human endogenous ribonuclease P (RP) to ensure the extracted test specimen
149 contains amplifiable RNA. The fluorescent signal intensity was captured using a real-time PCR
150 instrument called QuantStudio5 Real-Time PCR system (ThermoFisher Scientific).

151 *Dengue serotyping*

152 Following PCR screening, samples positive for DENV were serotyped from the same RNA extract
153 using CDC DENV 1-4 rRT-PCR Multiplex assay on the QuantStudio5 Real-Time PCR system.
154 The assay employed DENV 1-4 specific primers and probes provided by the CDC, USA. To
155 perform the assay, we mixed 5 μ l of extracted RNA templates with 12.5 μ l of the master mix
156 (SuperScript™ III One-Step RT-PCR System with Platinum™ Taq DNA Polymerase,
157 ThermoFischer Scientific). The assay was run in a multiplex format, with each serotype-specific
158 probe labeled with different probes as per the manufacturer's protocol.

159 *Dengue sequencing*

160 After serotyping, we selected specimens with PCR screening Ct values below 26 for sequencing.
161 Sequencing was carried out with technical support from CERI and KRISP. The primer scheme for
162 DENV sequencing and other arboviruses is available on the CLIMADE GitHub
163 (<https://github.com/CERI-KRISP/CLIMADE/tree/master/Protocols/Arboviruses>). The
164 COVIDSeq protocol was adapted to perform the library preparation, followed by sequencing on
165 the Illumina Miseq platform. This protocol is available on the CLIMADE GitHub website, and it
166 is described in detail by *Elaine Vieira Santos, Debora Glenda Lima de La Roque in protocols.io*
167 (<https://protocols.io/view/pathogen-whole-genome-sequencing-multiplexed-ampli-cgwbtxan>).

168 The libraries were prepared using the Illumina COVIDSeq protocol (Illumina Inc, USA). Briefly,
169 RNA was reverse transcribed to cDNA using random hexamers. The Dengue genome was
170 amplified using the two pools of primers specific for the Dengue serotype 1-4. PCR amplicons
171 were tagmented using the EBLTS (Enrichment BLT), which is a process that fragments and tags
172 the PCR amplicons with adaptor sequences. Adaptor ligated amplicons were further amplified

173 using the unique 10 base pair Index 1 (i7) adapters and Index 2 (i5) adapters (IDT for Illumina-
174 PCR Indexes Set 1) for each sample. The pooled amplicon library was quantified using a Qubit
175 2.0 fluorometer (Invitrogen, Inc.) and diluted to a 4 nM. The 4nM library was denatured and diluted
176 to a final loading concentration of 12pM. Dual indexed paired-end sequencing was performed on
177 the Illumina Miseq using a v3 600 cycle flow cell.

178 *Bioinformatics analysis*

179 Following base calling and demultiplexing of the sequence run, fastq files were processed using
180 the Genome Detective analysis pipeline version 2.13.3 (<https://www.genomedetective.com/>).
181 Upon completion, consensus fasta and Binary Alignment Map (BAM) files were retrieved from
182 Genome Detective for each individual sample. Sequence genotyping and lineage classification was
183 performed using the Genome Detective Dengue Typing Tool
184 (<https://www.genomedetective.com/app/typingtool/dengue/>), based on a newly developed
185 nomenclature for DENV classification (20). The resulting genomic sequences have been made
186 available on the GISAID Epi-Arbo database (EPI_ISL_19229161 - EPI_ISL_19229193).

187 *Sequence Alignment and Phylogenetic Analysis*

188 DENV reference datasets were retrieved from two primary databases: the National Centre for
189 Biotechnology Information (NCBI) GenBank and the GISAID Epi-Arbo web interface
190 (<https://gisaid.org/>). Any duplicate entries were removed. Sequence genotyping and lineage
191 classification was performed using the Genome Detective Dengue Typing Tool
192 (<https://www.genomedetective.com/app/typingtool/dengue/>), based on a newly developed
193 nomenclature for DENV classification (20). The retrieved sequences corresponding to the lineages
194 detected from newly sequenced Ethiopian genomes were subjected to initial quality control to
195 remove any unverified sequences and incomplete records (i.e. geographical location and sampling
196 dates). The final dataset used for the phylogenetic analyses in this study consisted of 33 sequences
197 generated in this study from Ethiopia, as well as 2348 publicly available sequences of DENV3
198 genotype III major lineage B (corresponding to one of the transmission lineages detected in
199 Ethiopia) and 990 sequences of DENV1 genotype III major lineage A (corresponding to the other
200 transmission lineage detected in Ethiopia). Our DENV1 and DENV3 datasets were aligned against
201 the appropriate DENV serotype reference genome (DENV1: NC_001477.1; DENV3:
202 NC_001475.2) using Nextalign v1.3.0 alignment tool (21).

203

204 Maximum likelihood trees for each of the two genotypes were generated using IQ-TREE v
205 2.2.2.2 with 1,000 bootstraps (22). The nucleotide substitution model TIM2+F+I+G4 was selected
206 for DENV1 and GTR+F+I+G4 for DENV3, respectively, according to Bayesian Information
207 Criterion using Model Finder (23). The molecular clock signal was evaluated using TempEst
208 v1.5.3 (24). Potential outliers that violated the molecular clock assumption were removed prior to
209 inferring a time-scaled tree (TreeTime v 0.10.0) using a molecular clock rate of 5.015×10^{-4} and
210 1.225×10^{-4} for DENV1 and DENV3 respectively nucleotide substitutions per site per year, as
211 determined by the clock function in TreeTime.

212

213 *Time-calibrated Bayesian phylogenies*

214 Time-calibrated Bayesian phylogenetic trees were constructed to estimate the time of emergence
215 (time to the most common recent ancestor, TMRCA) of the transmission lineages circulating
216 during the 2023 outbreak, and the likely introduction routes. The latest release of BEAST
217 (v.1.10.4) was used along with the BEAGLE library v3.2.0 to improve computational speed (25,
218 26). A relaxed clock model was applied for all analyses along with the HKY+G+I nucleotide
219 substitution model. A constant population coalescent model assumption was used. Subsequently,
220 all analyses were performed in two independent runs of 100 million iterations each. Convergence
221 of MCMC chains was checked using Tracer v.1.7.1 (27) and 10% of initial chains was discarded
222 as burn-in. Post-burn-in samples were pooled to summarize parameter estimates using
223 LogCombiner and TreeAnnotator, including posterior probability of each parameter and maximum
224 clade credibility (MCC) trees.

225 *Visualisations*

226 The phylogenetic trees were visualized using Figtree v1.4.4
227 (<http://tree.bio.ed.ac.uk/software/figtree/>) and other figures using R and ggplot (28).

228 *Air Travel Data*


229 We evaluated travel data generated from the International Air Transport Association (IATA) to
230 quantify passenger volumes originating from international airports into. IATA data accounts for
231 ~90% of passenger travel itineraries on commercial flights, excluding transportation via
232 unscheduled charter flights (the remainder is modeled using market intelligence).

233 *Ethical considerations*

234 The study obtained ethical approval from Addis Ababa University (Ref. no.
235 CNCSDO/175/15/2023), and Institutional Review Boards (IRBs) of the EPHI (EPHI-IRB-536-
236 2023).

237 **Results**

238 Participants were recruited during a recorded DENV outbreak in Ethiopia (Supplementary Figure
239 1). Cases were recorded in multiple regions of the country by the Ministry of Health (MoH) in
240 Ethiopia from early 2023, with Afar and Dire Dawa being the two most affected regions (Figure
241 1A, C). There was a first peak in cases in the Afar region between April and August 2023, low
242 level transmission in Dire Dawa over that period, and a second prominent peak in Dire Dawa from
243 October 2023 to January 2024. Our clinical surveillance was able to detect dengue acute infections
244 from both these regions, with detection in Dire Dawa intensifying prior to the peak in recorded
245 cases (Figure 1A).



246

247 **Figure 1. Spatiotemporal distribution of dengue epidemiology and ecology in Ethiopia.**

248 A) Epidemiological curve of dengue cases in Ethiopia: Afar region (outbreak from April 2023 to
249 August 2023), Dire Dawa City Administration (outbreak from June 2023 to April 2024), and
250 national count from 2023 to 2024. B) Serotype distribution of sampled cases. C) Map of DENV
251 cases in Ethiopia from 2023 to 2024, with the Afar region and Dire Dawa City administration
252 outlined in red. D) Demographic distribution of sampled cases.

253 *Sample collection and dengue epidemiology in Ethiopia*

254 Out of 891 febrile patients screened for DENV, CHIKV, and ZIKV infections, only dengue virus
 255 was detected in this study. The overall proportion with a positive PCR for DENV was 10.4% (93
 256 out of 891 patients). The test positivity was slightly higher in men than women (Table 1). DENV
 257 was isolated from two of the sites; the proportion with a positive DENV PCR was 13.7% (41/300)
 258 in Afar and 17.9% (52/291) in Dire Dawa. None of the 300 samples from Gambela were positive
 259 for DENV. Virus genotyping shows evidence of co-circulation of DENV1 and DENV3 throughout
 260 the outbreak period (Figure 1B). Of the 93 isolates, 88 (94.6%) were identified as belonging to the
 261 DENV3 serotype, while the remaining 5 (5.4%) were identified as DENV1. At the Afar site, only
 262 DENV3 was detected (n=36), whereas at the Dire Dawa site, both DENV1 (n=5) and DENV3
 263 (n=47) were detected (Table 1).

264

265 **Table 1:** *Socio-demographics characteristics, burden of DENV infection, and serotype circulation*
 266 *in Ethiopia.*

Parameters	Dengue test positive, n (%)			Total	Percentage positivity	Dengue serotypes		
		Yes	No			DENV1	DENV3	Total
Sex	Male	49	400	449	10.91	2	47	49
	Female	44	398	442	9.95	3	41	44
Region	Afar	41	259	300	13.67	0	41	41
	Dire Dawa	52	239	291	17.87	5	47	52
	Gambela	0	300	300	0	0	0	0
Age Groups (years)	0-4	0	27	27	0	0	0	0
	5-14	2	40	42	4.8	0	2	2
	15-29	41	393	434	9.4	2	40	42
	30-44	28	228	256	10.9	1	27	28
	>= 45	21	111	132	15.9	2	19	21

267


268

269 *Virus genome sequencing*

270 A total of 55 viral isolates were selected based on their PCR screening Ct values from Afar region
271 and Dire Dawa City administration. The Ct values of the isolates ranged from 15.5 to 25.6. A total
272 of 20 DENV3 were selected from Afar and 35 (5 DENV1 and 30 DENV3) were selected from
273 Dire Dawa sites. Out of these, 54 isolates were successfully sequenced, and only one sample failed
274 to be sequenced due to low sample volume. Among the successfully sequenced isolates, 33 gave
275 near whole genome sequences (>90% genome coverage). Of these, all of the 5 DENV1 identified
276 as DENV1 genotype III major lineage A (DENV1_IIIA), while the remaining 28 were identified
277 as DENV3 genotype III major lineage B (DENV3_IIIB), with 1 isolate from Afar and 27 from
278 Dire Dawa (Figure 2).

279 Samples collected from Dire Dawa demonstrated an expected association between a high viral
280 load (lower Ct values) and high sequence coverage whereas most samples from Afar resulted in
281 low sequence coverage genomes despite low Ct values. The Ct values were not repeated after
282 storing the serum samples; we only used the first screening PCR Ct values. The sample collection
283 and storage freezers used were different for both sites. The samples from Afar site were collected
284 in DNA/RNA shield during the outbreak in May 2023 and stored for a long time at -20°C, with
285 intermittent temperature fluctuations of the freezer. In contrast, samples collected from Dire Dawa
286 and Gambela sites were relatively recent and stored at -80°C until they were sequenced.

287



288

289 **Figure 2. Sequencing process and coverage results.** A) Sample selection, genotyping and
290 sequencing workflow. B) CT values versus sequence coverage for all sequenced specimens.

291

292 *Evolutionary history of sequences belonging to Ethiopia's 2023 outbreak*

293 A phylogenetic tree was reconstructed with 990 global DENV1_III A aligned sequences, including
294 five from Ethiopia sequenced in this study (Figure 3A). For this lineage, all sequences from
295 Ethiopia belonged to a single transmission cluster, which clustered monophyletically, with other
296 African sequences (Democratic Republic of Congo and Djibouti), suggesting cryptic transmission
297 in the region since 2019 (Figure 3B). TMRCA of the Ethiopian clade specifically to mid 2021
298 (Figure 3B). Basal to this African clade are sequences mostly of Asian origin suggested an
299 introduction into Africa from Asia, which we can date back to the year 2018 (Figure 3B). For the
300 DENV3_IIIB lineage, we constructed a phylogenetic tree with 2,348 global sequences, including
301 the ones from Ethiopia (Figure 3C). Sequences from Ethiopia belong to two distinct clades on the
302 tree (Figure 3D, E). While the first clade consisted of sequences generally of Asian and African
303 origin, the Ethiopian sequences, with a TMRCA of early 2021 (95% HPD: 2020 – 2022) cluster

304 monophyletically with a sequence from Italy's 2023 outbreak (29). We infer that the common
305 ancestor between the Ethiopian isolates and the Italy one existed around mid-2019 (95% HPD:
306 mid-2017 - 2021) with long branches separating the two locations. The Ethiopia-Italy clade is
307 supported with >70% posterior support at the relevant internal nodes on the MCC tree. This
308 suggests some level of cryptic transmission in unsampled areas from where both Ethiopia and Italy
309 could have received viral introductions. However, given historical ties between the two countries
310 and the remaining high connectivity, Italy being the European country with the second most air
311 travel passengers into Ethiopia (Supplementary Figure 2), an introduction from there is plausible.
312 The second relevant clade of this lineage shows a clear introduction from Asia to Ethiopia late
313 2021 (95% HPD: 2021 - 2023), with potential persistent transmission since then (Figure 3E).
314 While the closest relatives to this Ethiopian clade are sequences from India, it remains possible,
315 again given long branch lengths on the tree, that intermediate unsampled regions are involved,
316 including country such as Saudi Arabia (30), which is the top countries with largest passenger
317 volume to Ethiopia (Supplementary Figure 2).


318

319

320

321

322



323

324 **Figure 3. Phylogenetic analysis of Ethiopian genomes.** A) Timed maximum likelihood phylogeny
325 of the DENV1 genotype III major lineage A clade, containing Ethiopian genomes sequenced in
326 this study. The tree is coloured by sequence locations. B) Zoom-in of a sub-clade of the tree to
327 show close evolutionary relationships related to the Ethiopian DENV1 genomes. C) Timed
328 maximum likelihood phylogeny of the DENV3 genotype III major lineage B clade, containing
329 Ethiopian genomes sequenced in this study. The tree is coloured by sequence locations. D)
330 Maximum clade credibility (MCC) tree of sub-tree containing cluster 1 of Ethiopian DENV3

331 *genomes. E) Maximum clade credibility (MCC) tree of sub-tree containing cluster 2 of Ethiopian*
332 *DENV3 genomes.*

333 **Discussion**

334 In this study, we investigated the genomic epidemiology of DENV in two areas of Ethiopia. This
335 study presents the distribution of serotypes and first-ever report of the genotypes and lineages
336 circulating in Ethiopia from the first ever whole genomes sequenced in the country.

337 Our analysis showed that two serotypes, DENV1 and DENV3 were isolated from Dire Dawa,
338 while only DENV3 was isolated in the Afar area. These preliminary data suggest a need for more
339 comprehensive epidemiological or genomic surveillance and strengthened systems for severe
340 dengue surveillance due to the potential risk of severe dengue from multiple serotypes or
341 genotypes. In Africa, all four serotypes of DENV have been detected in both humans and *Aedes*
342 mosquitoes (31). DENV2 is the most prevalent serotype in the East African region. The virus
343 caused outbreaks in Ethiopia in 2013, Kenya in 2013, Tanzania in 2014, and Mozambique in 2014-
344 2015, and has continued to remain prevalent in these areas (32-34). DENV1 outbreaks have been
345 detected at different times in Angola, Kenya, Senegal, and Somalia (35). The current DENV1
346 serotype may have been historically co-circulating with DENV2 or may have been a recent
347 introduction into Dire Dawa.

348 The current outbreak of dengue fever first began in the Mile district of the Afar Region in Ethiopia
349 in April 2023, in which the outbreak was caused by DENV3 and has since spread to at least five
350 other regions in the Eastern part of the country (36). Between April 2, 2023, and February 26,
351 2024, dengue cases were reported to the Public Health Emergency Operations Center in Ethiopia
352 from these affected regions.

353 Phylogenetic analysis revealed that the DENV1 serotype belongs to genotype III major lineage A.
354 The analysis also showed that the circulation of this lineage during the 2023 outbreak corresponds
355 to a single transmission cluster. It seems that this cluster was introduced to Ethiopia from Asia via
356 other African countries. Dengue viruses belonging to the same genotype were sequenced during
357 the 2023 dengue outbreak in Chad (2). However, the Ethiopian genomes generated in this study
358 are not directly linked to the outbreak in Chad, which originated from a large outbreak in Tanzania
359 in 2019, via Nigeria (37). The phylogenetic reconstruction from available DENV1 genomic data

360 in Africa, which we have supplemented with our sequences, show that several distinct lineages are
361 currently circulating on the continent. All known Central African DENV1 strains belong to the
362 genotype V African lineage, with the oldest strains of this lineage being isolated in Nigeria in 1968
363 (38). However, it remains that the lack of publicly available data limits our understanding of the
364 dynamics of DENV1 within the continent.

365 On the other hand, the DENV3 viruses sequenced during Ethiopia's 2023 outbreak belonged to
366 the genotype III major lineage B, and phylogenetic reconstructions revealed two transmission
367 clusters circulating in Ethiopia. Cluster-1 is closely related to a DENV3 virus sequenced in 2023
368 sequence from Italy (as shown in Figure 3A) (29). This highlights the possibility that the virus
369 may have been introduced into Ethiopia from Italy. Since we have no previous sequence
370 information, we cannot exclude the possibility of transmission from Ethiopia to Italy.


371 Available data indicates that DENV3 genotype III exists in neighboring countries such as Sudan,
372 Kenya, Djibouti, and Somalia (39). However, the current DENV3 genotype III in Ethiopia is not
373 directly related to the African isolates. Cluster-2 appears to have been introduced from India
374 perhaps via secondary locations (as shown in Figure 3E). Phylogenetic analysis of DENV3 in India
375 has shown that outbreaks were caused by genotype III and the outbreak during 2017-2018 was
376 similar to the strain that was circulating in 2016 (40).

377 While performing the whole genome sequencing, only 33 samples resulted in approximately 90%
378 and above genome coverage. Thirty-two (DENV1 =5 and DENV3 =27) of these samples were
379 from Dire Dawa site but only one sample gave approximately 90% genome coverage from Afar
380 site. Serum samples from the Afar site was collected during the outbreak in tubes containing
381 DNA/RNA shield solution and sent to the Ethiopian Public Health Laboratory for detection and
382 serotyping. The remaining samples were then stored at -20°C for around 11 months before
383 sequencing. Sequencing was carried out following this period of storage. The limited genome
384 coverage observed could be attributed to the extended storage under unsuitable conditions. In
385 contrast, serum samples obtained from Dire Dawa were gathered without DNA/RNA shield and
386 were relatively recent, stored at -80°C for approximately 4 to 8 months, resulting in greater
387 sequence coverage.

388

389 This study presents the first report on the genomic epidemiology of the 2023 dengue outbreak in
390 Ethiopia. However, it is important to note some limitations: 1) Poor sequencing outcomes were
391 encountered, possibly due to inadequate sample storage at Afar. Improved sample storage
392 conditions could have led to better whole genome sequencing results. 2) The limited availability
393 of DENV sequences continentally and globally restricts our ability to infer global transmission
394 dynamics and direct introduction routes. In this study, we investigated the cocirculation of DENV1
395 and DENV3 in Ethiopia during the 2023 outbreak. We were able to identify circulation genotypes
396 and lineages and infer possible introduction routes and timings. Our findings highlight the utility
397 for comprehensive disease surveillance, including pathogen genome sequencing, of dengue
398 transmission in Ethiopia and beyond to understand transmission dynamics of emerging outbreaks.
399 Regular active surveillance through highly connected sentinel sites as well as at port of entry can
400 improve response time to outbreaks and reduce the likelihood of dengue establishment.


401 **Supplementary Materials**



402
403 **Supplementary Figure 1:** Map showing the location of hospital-based sentinel sites where
404 samples were collected for the study. The Afar region and Dire Dawa City administration are

405 located in the eastern part of Ethiopia, while the Gambela region is situated in the western part of
406 Ethiopia.

407



408

409 **Supplementary Figure 2:** Monthly incoming travel into Ethiopia from countries with >2000
410 incoming passengers. The data shown is for February 2020 as a representative month.

411

412 **Supplementary Table 1:** Acknowledgement of Authors for data obtained from the GISAID
413 EpiArbo database.

414

415 **Author Contributions**

416 Ad.A. and D.B. conceived and designed the experiments; AdA., H.T. and E.W. performed the data
417 analysis and experiments; Ab.A., F.R., M.B., H.T., K.K., C.H., M.U.G.K, T.d.O. contributed
418 materials/analysis tools; J.G., and S.P. participated in the wet laboratory work; Ge.Ta., Ge.To.,
419 D.B., R.de.W.T., T.d.O., D.W., supervised the work; and Ad.A., H.T. E.W., and D.B. wrote the
420 original manuscript and the paper. All authors have read and agreed to the published version of
421 the manuscript.

422 **Funding**

423 Support was provided by the Ethiopian Public Health Institute and Addis Ababa University.
424 Sequencing and modelling activities at KRISP and CERI are supported in part by grants from the
425 Rockefeller Foundation (HTH 017), the Abbott Pandemic Defense Coalition (APDC), the National
426 Institute of Health USA (U01 AI151698) for the United World Antivirus Research Network
427 (UWARN), the SAMRC South African mRNA Vaccine Consortium (SAMVAC), Global Health
428 EDCTP3 Joint Undertaking and its members as well as Bill & Melinda Gates Foundation
429 (101103171), European Union's Horizon Europe Research and Innovation Programme
430 (101046041), the Health Emergency Preparedness and Response Umbrella Program (HEPR
431 Program), managed by the World Bank Group (TF0B8412), the GIZ commissioned by the
432 Government of the Federal Republic of Germany, the UK's Medical Research Foundation (MRF-
433 RG-ICCH-2022-100069), and the Wellcome Trust for the Global health project (228186/Z/23/Z,
434 also M.U.G.K.). The EU project EpiGen (<https://epigenethiopia.org/>) is gratefully acknowledged
435 for complementary support. The content and findings reported herein are the sole deduction, view
436 and responsibility of the researcher/s and do not reflect the official position and sentiments of the
437 funding agencies. M.U.G.K. acknowledges funding from The Rockefeller Foundation,
438 Google.org, the Oxford Martin School Pandemic Genomics programme, European Union's
439 Horizon Europe programme projects MOOD (#874850) and E4Warning (#101086640), the John
440 Fell Fund, a Branco Weiss Fellowship and Wellcome Trust grants 225288/Z/22/Z, United
441 Kingdom Research and Innovation (#APP8583) and the Medical Research Foundation (MRF-RG-
442 ICCH-2022-100069). The contents of this publication are the sole responsibility of the authors and
443 do not necessarily reflect the views of the European Commission or the other funders.

444 **Informed Consent Statement**

445 All participants gave written informed consent for participation and publication.

446 **Data Availability Statement**

447 All sequences used for this manuscript are publicly available on the GISAID EpiArbo database,
448 subject to its terms and conditions (<https://www.gisaid.org/>), GISAID identifier:
449 EPI_ISL_19229161 - EPI_ISL_19229193.

450 **Acknowledgments**

451 Concerning our reference data against which we analysed the genomes generated in this study,
452 where a portion of those were obtained from the GISAID EpiArbo database, we gratefully
453 acknowledge Authors from the Originating laboratories responsible for obtaining the specimens,
454 as well as the Submitting laboratories where the genome data were generated and shared via
455 GISAID (See Supplementary Table 1). Additionally, we extend our gratitude to CDC Atlanta for
456 supplying Dengue detection and serotyping kits.

457 **Conflicts of Interest**

458 K.K. is the founder of BlueDot, a social enterprise that develops digital technologies for public
459 health. C.H. is employed at BlueDot. All other authors declare no competing interests or personal
460 relationships that could influence this research paper.

461 **Abbreviations**

462	BAM	Binary Alignment Map
463	CDC	Center for Diseases Control and prevention
464	CERI	Center for Emerging and Re-emerging Infectious diseases
465	CHIKV	Chikungunya virus
466	CLIMADE	Climate Amplified Diseases and Epidemics
467	COVID-19	Corona Virus Diseases-19
468	DENV	Dengue virus
469	EPHI	Ethiopian Public Health Institute
470	GISAID	Global initiative on sharing all influenza data
471	HPD	Highest Posterior Density
472	IATA	International Air Transport Association
473	IRB	Institutional Review Board
474	KRISP	KwaZulu-Natal Research Innovation and Sequencing Platform
475	MCC	Maximum Clade Credibility

476	NCBI	National Centre for Biotechnology Information
477	RT-PCR	Reverse transcription polymerase chain reaction
478	TMRC	The Most Common Recent Ancestor
479	ZIKV	Zika virus
480		
481		

482 **References**

- 483 1. World Health Organization. Disease Outbreak News; Dengue – Global situation. 2023.
484 Available at: <https://www.who.int/emergencies/disease-outbreak-news/item/2023-DON498>.
- 485 2. WHO African Region Health Emergency Situation Report-Multi-country Outbreak of Dengue,
486 Consolidated Regional Situation Report # 001. 2023.
- 487 3. Ethiopia Steps Up Actions for Dengue Prevention and Control. World Health Organization
488 Africa. 2014. Available from: [https://www.afro.who.int/news/ethiopia-steps-actionsdengue-](https://www.afro.who.int/news/ethiopia-steps-actionsdengue-prevention-and-control)
489 [prevention-and-control](https://www.afro.who.int/news/ethiopia-steps-actionsdengue-prevention-and-control).
- 490 4. Ahmed YM, Salah A.A. Epidemiology of Dengue Fever in Ethiopian Somali Region:
491 Retrospective Health Facility Based Study. *Central African Journal of Public Health*. 2016; 2(2):
492 51-56. doi: 10.11648/j.cajph.20160202.12.
- 493 5. Gutu MA, Bekele A, Seid Y, Mohammed Y, Gemechu F, Woyessa AB, *et al*. Another dengue
494 fever outbreak in Eastern Ethiopia—An emerging public health threat. *PLoS Negl Trop Dis* 2021;
495 15(1): e0008992. <https://doi.org/10.1371/journal.pntd.0008992>.
- 496 6. Hasan M.M, Hernandez-Y P.J., Rivera-Cabrera M.A., Sarkar A., Santos Costa A.C., Essar M.Y.
497 Concurrent epidemics of dengue and COVID-19 in Peru: Which way forward? *The Lancet*
498 *Regional Health – Americas*. 2022;12: 100277. <https://doi.org/10.1016/j.lana.2022.100277>.
- 499 7. Andhikaputra, G., Lin, YH., Wang, YC. Effects of temperature, rainfall, and El Niño Southern
500 Oscillations on dengue-like-illness incidence in Solomon Islands. *BMC Infect Dis*. 2023; 23: 206.
501 <https://doi.org/10.1186/s12879-023-08188-x>.
- 502 8. Murugesan A, Manoharan M. Dengue Virus. In book of Emerging and Reemerging Viral
503 Pathogens. Chapter 2. 2020: 281-359. <https://doi.org/10.1016/B978-0-12-819400-3.00016-8>.
- 504 9. Mustafa M.S., Rasotgi V., Jain S., Gupta V. Discovery of fifth serotype of dengue virus (DENV-
505 5): A new public health dilemma in dengue control. *Medical Journal Armed Forces India*. 2015;
506 71(1): 67-70. <https://doi.org/10.1016/j.mjafi.2014.09.011>.
- 507 10. Poltep K., Phadungsombat J., Nakayama E.E., Kosoltanapiwat N., Hanboonkunupakarn B.,
508 Wiriyarat W., Shioda, T., Leungwutiwong P., Genetic Diversity of Dengue Virus in Clinical
509 Specimens from Bangkok, Thailand, during 2018–2020: Co-Circulation of All Four Serotypes
510 with Multiple Genotypes and/or Clades. *Trop. Med. Infect. Dis*. 2021; 6:162.
511 <https://doi.org/10.3390/tropicalmed6030162>.
- 512 11. Calvez E, Somlor S, Viengphouthong S, Balière C, Bounmany P, Keosenhom S, *et al*. Rapid
513 genotyping protocol to improve dengue virus serotype 2 survey in Lao PDR. *PLoS ONE*. 2020;
514 15(8): e0237384. <https://doi.org/10.1371/journal.pone.0237384>.
- 515 12. Li L., Guo X., Zhang X., Lingzhai Zhao L., Li L., Wang Y., *et al*. A unified global genotyping
516 framework of dengue virus serotype-1 for a stratified coordinated surveillance strategy of dengue
517 epidemics. *Infect Dis Poverty*. 2022; 11:107. <https://doi.org/10.1186/s40249-022-01024-5>.

- 518 13. Naveca F., Santiago G. A., Maito R., Ribeiro Meneses C., do Nascimento V., de Souza V.,
519 Bello G. Reemergence of Dengue Virus Serotype 3, Brazil, 2023. *Emerging Infectious Diseases*.
520 2023; 29(7):1482-1484. <https://doi.org/10.3201/eid2907.230595>.
- 521 14. Hill V, Cleemput S, Fonseca V, Tegally H, Brito AF, Gifford R, et al., A new lineage
522 nomenclature to aid genomic surveillance of dengue virus. *medRxiv [Preprint]*. 2024 May
523 17:2024.05.16.24307504. doi: 10.1101/2024.05.16.24307504.
- 524 15. Rahim R, Hasan A, Phadungsombat J, Hasan N, Ara N, Biswas SM, Nakayama EE, Rahman
525 M, Shioda T. Genetic Analysis of Dengue Virus in Severe and Non-Severe Cases in Dhaka,
526 Bangladesh, in 2018-2022. *Viruses*. 2023;15(5):1144. doi: 10.3390/v15051144.
- 527 16. Ahamed S.F., Rosario V., Britto C., Dias M., Nayak K., Chandele A., Kaja M-K., Shet A.
528 Emergence of new genotypes and lineages of dengue viruses during the 2012–15 epidemics in
529 southern India. *International Journal of Infectious Diseases*. 2019; 84 (2019): S34-S43.
530 <https://doi.org/10.1016/j.ijid.2019.01.014>.
- 531 17. Durbin AP, Whitehead SS. Next-Generation Dengue Vaccines: Novel Strategies Currently
532 Under Development. *Viruses*. 2011; 3(10):1800-1814. <https://doi.org/10.3390/v3101800>.
- 533 18. Asebe G, Michlmayr D, Mamo G, Abegaz WE, Endale A, Medhin G, et al. Seroprevalence of
534 Yellow fever, Chikungunya, and Zika virus at a community level in the Gambella Region, South
535 West Ethiopia. *PLoS ONE*. 2021; 16(7): e0253953. <https://doi.org/10.1371/journal.pone.0253953>.
- 536 19. Horstick O., Martinez E., Guzman M. G., Martin J. L., Ranzinger S. R. WHO dengue case
537 classification 2009 and its usefulness in practice: an expert consensus in the Americas. *Pathogens*
538 and global health. 2015; 109(1), 19–25. <https://doi.org/10.1179/2047773215Y.0000000003>.
- 539 20. Hill V, Cleemput S, Fonseca V, Tegally H, Brito AF, Gifford R, et al., A new lineage
540 nomenclature to aid genomic surveillance of dengue virus. *medRxiv [Preprint]*. 2024. doi:
541 10.1101/2024.05.16.24307504.
- 542 21. Aksamentov I., Roemer C., Hodcroft E., Neher R. Nextclade: clade assignment, mutation
543 calling and quality control for viral genomes. *J Open Source Softw*. 2021; 6:3773.
- 544 22. Nguyen L.T, Schmidt HA, von Haeseler A, Minh B. Q. IQ-TREE: a fast and effective
545 stochastic algorithm for estimating maximum-likelihood phylogenies. *Mol. Biol. Evol*. 2015; 32:
546 268-274.
- 547 23. Rambaut A, Lam TT, Max Carvalho L, Pybus OG. Exploring the temporal structure of
548 heterochronous sequences using TempEst (formerly Path-O-Gen). *Virus Evol*. 2016; 2: vew007.
- 549 24. Sagulenko P, Puller V, Neher RA. TreeTime: maximum-likelihood phylodynamic analysis.
550 *Virus Evol*.2018; 4: vex042.
- 551 25. Suchard MA, Lemey P, Baele G, Ayres DL, Drummond AJ, Rambaut A. Bayesian
552 phylogenetic and phylodynamic data integration using BEAST 1.10. *Virus Evol*. 2018; 8;4(1):
553 vey016. doi: 10.1093/ve/vey016.

- 554 26. Ayres DL, Darling A, Zwickl DJ, Beerli P, Holder MT, Lewis PO, et al. BEAGLE: An
555 Application Programming Interface and High-Performance Computing Library for Statistical
556 Phylogenetics. *Syst. Biol.* 2012; 61(1):170-173. <https://doi.org/10.1093/sysbio/syr100>.
- 557 27. Rambaut A, Drummond AJ, Xie D, Baele G, Suchard MA. Posterior summarization in
558 Bayesian phylogenetics using Tracer 1.7. *Syst. Biol.* 2018; 67: 901-904.
- 559 28. Wickham H. *ggplot2: Elegant Graphics for Data Analysis*. Springer New York, NY. 2016.
560 <https://doi.org/10.1007/978-0-387-98141-3>.
- 561 29. Branda F, Nakase T, Maruotti A, Scarpa F, Ciccozzi A, Romano C, et al., Dengue virus
562 transmission in Italy: surveillance and epidemiological trends up to 2023. medRxiv. 2023;
563 12:1923300208; doi: <https://doi.org/10.1101/2023.12.19.23300208>.
- 564 30. Hashem AM, Sohrab SS, El-Kafrawy SA, Abd-Alla AMM, El-Ela SA, Abujamel TS, et al.,
565 Diversity of dengue virus-3 genotype III in Jeddah, Saudi Arabia. *Acta Trop.* 2018;183:114-118.
566 doi: 10.1016/j.actatropica.2018.04.002.
- 567 31. Amarasinghe A, Kuritsk JN, Letson GW, Margolis HS. Dengue virus infection in Africa.
568 *Emerg Infect Dis.* 2011;17(8):1349-54. doi: 10.3201/eid1708.101515.
- 569 32. Woyessa AB, Mengesha M, Kassa W, Kifle E, Wondabeku M, Girmay A, Kebede A. et al.
570 The first acute febrile illness investigation associated with dengue fever in Ethiopia, 2013: A
571 descriptive analysis. *Ethiop. J. Health Dev.* 2014;28(3):155-161.
- 572 33. Ellis EM, Neatherlin JC, Delorey M, Ochieng M, Mohamed AH, Mogeni DO, et al. A
573 Household Serosurvey to Estimate the Magnitude of a Dengue Outbreak in Mombasa, Kenya,
574 2013. *PLoS Negl Trop Dis.* 2015; 9(4): e0003733. <https://doi.org/10.1371/journal.pntd.0003733>.
- 575 34. Mboera LEG, Mweya CN, Rumisha SF, Tungu PK, Stanley G, Makange MR, et al. The Risk
576 of Dengue Virus Transmission in Dar es Salaam, Tanzania during an Epidemic Period of 2014.
577 *PLoS Negl Trop Dis.* 2016; 10(1): e0004313. <https://doi.org/10.1371/journal.pntd.0004313>.
- 578 35. Diallo D., Diouf B., Gaye A., hadji Ndiaye E., Sene N.M., Dia I., et al. Dengue vectors in
579 Africa: A review. *Heliyon.* 2022; 8(5): e09459. <https://doi.org/10.1016/j.heliyon.2022.e09459>.
- 580 36. Ethiopian Public Health Institute. Public Health Emergency Operations Center (PHEOC),
581 Ethiopia. *Weekly Bulletin.* 2024; Bulletin number 61.
- 582 37. WHO. *Weekly Bulletin on Outbreaks and Other Emergencies; Week 46.* Geneva, Switzerland:
583 WHO Regional Office for Africa; 2019.
- 584 38. Carey D.E., Causey O.R., Reddy S., Cooke A.R. Dengue viruses from febrile patients in
585 Nigeria, 1964-68. *The Lancet.* 1971; 297(7690): 105-106. [https://doi.org/10.1016/S0140-](https://doi.org/10.1016/S0140-6736(71)90840-3)
586 [6736\(71\)90840-3](https://doi.org/10.1016/S0140-6736(71)90840-3).
- 587 39. Selhorst P., Lequime S., Dudas G., Proesmans S., Lutumba P., Katshongo F et al.
588 Phylogeographic analysis of dengue virus serotype 1 and cosmopolitan serotype 2 in Africa.
589 *International Journal of Infectious Diseases.* 2023; 133: 46-52.
590 <https://doi.org/10.1016/j.ijid.2023.04.391>.

591 40. Padhi A, Gupta E, Singh G, Parveen S, Islam A, Tarai B. Circulation of DENV-3 Genotype 3
592 during 2017 to 2018 in Delhi: A Single-Center Hospital-Based Study. *J Lab Physicians*. 2021;
593 14;14(1):21-26. doi: 10.1055/s-0041-1734017.

594

595

596